Short Interest in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Drops By 8.9%

Avalo Therapeutics, Inc. (NASDAQ:AVTXGet Free Report) saw a significant decline in short interest in the month of September. As of September 30th, there was short interest totalling 54,200 shares, a decline of 8.9% from the September 15th total of 59,500 shares. Approximately 0.6% of the shares of the company are short sold. Based on an average trading volume of 17,700 shares, the days-to-cover ratio is currently 3.1 days.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Affinity Asset Advisors LLC purchased a new stake in shares of Avalo Therapeutics in the first quarter valued at approximately $218,000. Ikarian Capital LLC purchased a new stake in shares of Avalo Therapeutics in the first quarter valued at approximately $1,015,000. Finally, Logos Global Management LP purchased a new stake in shares of Avalo Therapeutics in the second quarter valued at approximately $6,722,000. 87.06% of the stock is owned by institutional investors and hedge funds.

Avalo Therapeutics Price Performance

Shares of NASDAQ:AVTX opened at $9.29 on Tuesday. Avalo Therapeutics has a 12-month low of $3.95 and a 12-month high of $42.34. The business has a 50 day moving average of $9.22 and a two-hundred day moving average of $11.52.

Avalo Therapeutics (NASDAQ:AVTXGet Free Report) last announced its quarterly earnings results on Monday, August 12th. The company reported ($14.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($6.70) by ($7.37). As a group, equities analysts anticipate that Avalo Therapeutics will post -7.78 earnings per share for the current year.

Avalo Therapeutics Company Profile

(Get Free Report)

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.

Recommended Stories

Receive News & Ratings for Avalo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.